Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data

Regeneron Pharmaceuticals, Inc.'s two-antibody cocktail treatment for COVID-19 could potentially present a therapeutic option for people with compromised immune systems living with those who are infected, based on interim Phase III data the company announced on 26 January showing that it reduced symptomatic infections.

If the confirmatory data – expected early in the second quarter – are also positive, casirivimab/imdevimab (REGEN-COV or REGN-COV) would become the second antibody therapy to double as a treatment and a preventive drug for SARS-CoV-2 infection. The combination was granted emergency use authorization by the US Food and Drug Administration in November for use in patients over 12 with mild-to-moderate disease at risk of developing serious disease or needing hospitalization